SpectraCure AB TEMP

As of June 30, 2026, SpectraCure AB TEMP has 776.91M shares outstanding.

As of June 30, 2026, SpectraCure AB TEMP maintains a current ratio of 0.79, meaning it holds 0.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 9.53, indicating elevated leverage, while an interest coverage ratio of -14.36 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, SpectraCure AB TEMP posted a negative return on equity (ROE) of -48.61, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -38.83, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 13.75, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, SpectraCure AB TEMP recorded 41,000.00 in income tax expense. The company reported a pretax loss of -55.49M and -55.53M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on August 26, 2026, SpectraCure AB TEMP's stock has declined approximately 85.02% over the past 52 weeks.

Over the twelve months ended June 30, 2026, SpectraCure AB TEMP generated - - in revenue and converted that into -55.53M in net income, yielding earnings per share of -0.07. EBITDA reached -24.04M, while operating income came in at -54.04M.

As of June 30, 2026, SpectraCure AB TEMP holds 7.63M in cash and equivalents against 8.91M in total debt, resulting in a net debt position of -7.63M. Total book value stands at 93.58M, with working capital of -2.69M providing operational flexibility.

SpectraCure AB TEMP produced -32.14M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -18.84M in capital expenditures, free cash flow totaled -50.99M - equivalent to -0.07 per share.